Diabetes mellitus is a major cause of morbidity and mortality in the United States, and individuals with impaired glucose tolerance (IGT) or a history of gestational diabetes (GDM) are at increased risk of developing this disease. Research to test whether it is possible to prevent the occurrence of NIDDM is a national priority. The University of Pittsburgh proposes a primary prevention trial that optimally tests the hypothesis that NIDDM is preventable through weight loss and physical activity and simultaneously addresses whether an intervention that is more easily adopted by the health care system is of benefit. Targeted advertisement and chart review will be used to identify 100 subjects with IGT (confirmed on repeat OGTT and with at least one 2-hour BS>170); 100 GDM subjects will be identified from a registry of over 1000 women with GDM;
we aim for 40% of participants to be African American. These 200 high risk subjects will be randomized to a control group, a standard life-style intervention (SLI), or an enhanced life-style intervention (ELSI). The goals for the two intervention groups will be a 10% weight loss and 3 hours/week of physical activity. To achieve these goals, the SLI group will participate in a standard diet/exercise program that could be easily implemented by the health system; community-led exercise groups will also be available. The ELSI group will be given enhanced treatment to optimally test the prevention hypothesis; these subjects will be seen individually on a monthly basis; intervention will be prescribed as needed to achieve and maintain the weight and exercise goal. The primary outcome will be development of NIDDM (WHO criteria; confirmed by second test). Other endpoints will be changes in glucose, insulin resistance, insulin secretion, and the cardiovascular risk profile. During screening, some subjects will be identified as having non-fasting diabetes (NFD; FBS <140; 2 hour BS>200). These subjects will participate in a secondary prevention trial using a 2 x 2 factorial design with the two life-style conditions (SLI vs ESLI) crossed with 2 drug conditions (metformin vs placebo). The primary outcome measures for this secondary prevention study will be development of fasting hyperglycemia and incidence or progression of diabetic complications. The University of Pittsburgh is well qualified to participate in this trial as we have extensive experience in life-style interventions, exercise, clinical trials, diabetic complications, and in the medical management of diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DK048412-05
Application #
2734172
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Garfield, Sanford A
Project Start
1994-08-15
Project End
2001-06-30
Budget Start
1998-09-30
Budget End
1999-06-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Psychiatry
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
de Groot, Mary; Marrero, David; Mele, Lisa et al. (2018) Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program. Psychosom Med 80:167-173
Kim, Catherine; Aroda, Vanita R; Goldberg, Ronald B et al. (2018) Androgens, Irregular Menses, and Risk of Diabetes and Coronary Artery Calcification in the Diabetes Prevention Program. J Clin Endocrinol Metab 103:486-496
Perreault, L; Pan, Q; Aroda, V R et al. (2017) Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabet Med 34:1747-1755
Herman, William H; Pan, Qing; Edelstein, Sharon L et al. (2017) Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care 40:1668-1677
Billings, Liana K; Jablonski, Kathleen A; Warner, A Sofia et al. (2017) Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. J Clin Endocrinol Metab 102:2678-2689
Mercader, Josep M; Liao, Rachel G; Bell, Avery D et al. (2017) A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes. Diabetes 66:2903-2914
Aroda, Vanita R; Knowler, William C; Crandall, Jill P et al. (2017) Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia 60:1601-1611
Rockette-Wagner, Bonny; Storti, Kristi L; Dabelea, Dana et al. (2017) Activity and Sedentary Time 10 Years After a Successful Lifestyle Intervention: The Diabetes Prevention Program. Am J Prev Med 52:292-299
Crandall, Jill P; Mather, Kieren; Rajpathak, Swapnil N et al. (2017) Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care 5:e000438
Venditti, Elizabeth M (2017) Behavioral lifestyle interventions for the primary prevention of type 2 diabetes and translation to Hispanic/Latino communities in the United States and Mexico. Nutr Rev 75:85-93

Showing the most recent 10 out of 32 publications